Table 2 Clinical characteristics of the study population, Sousse, Tunisia, 2021
From: Risk factors for severe Covid-19 breakthrough infections: an observational longitudinal study
N | % | Median (IQ25%-IQ75%) | Specific cumulative incidence rate/100000 inhabitants | |
|---|---|---|---|---|
Comorbidities | ||||
No | 317 | 51.0 | ||
Cardiovascular diseases | 220 | 35.4 | ||
Diabetes | 139 | 22.4 | ||
Chronic respiratory diseases | 25 | 4.0 | ||
Immunity system diseases | 15 | 2.4 | ||
Others* | 40 | 6.5 | ||
Tobacco use | ||||
Yes | 111 | 17.9 | ||
No | 510 | 82.1 | ||
Vaccination schema | ||||
Incomplete | 449 | 72.3 | 1062.1 | |
Complete | 172 | 27.7 | 263.5 | |
Vaccine | ||||
AstraZeneca | 57 | 9.3 | 379.0 | |
CoronaVac | 98 | 15.6 | 702.4 | |
Pfizer BioNTech | 424 | 68.9 | 581.2 | |
Sinopharm | 16 | 2.7 | 823.7 | |
Sputnik | 15 | 2.4 | 1551.2 | |
Others (Moderna and Janssen) | 7 | 1.1 | 792.7 | |
Categories of vaccines** | ||||
RNA based vaccine | 425 | 69.3 | ||
Viral Vector | 74 | 12.1 | ||
Inactivated virus | 114 | 18.6 | ||
Self-estimation of adherence to preventive measure | ||||
Poor (score ≤ 4) | 58 | 9.3 | ||
Medium (5 ≤ score ≤ 7) | 323 | 52.0 | ||
High (score ≥ 8) | 240 | 38.6 | ||
Delay first dose and COVID19 infection | 19 (10–31) | |||
Delay second dose and COVID19 infection | 53 (19–73) | |||
Symptoms | ||||
Yes | 539 | 86.8 | ||
No | 82 | 13.2 | ||
Severity of disease | ||||
Asymptomatic or mild disease | 562 | 91.0 | ||
Home care oxygen or non- ICU*** hospitalization | 43 | 6.9 | ||
ICU*** hospitalization | 13 | 2.1 | ||
Death | 11 | 1.8 |